Undergraduate Degree

  • Amherst College , 1989 , Amherst , MA

Medical School

  • Harvard Medical School , 1995 , Boston , MA


  • Massachusetts General Hospital , 1996 , Boston , MA


  • Massachusetts General Hospital , 1999 , Boston , MA


  • Brigham & Women's Hospital , 2004 , Boston , MA


  • Boston Children's Hospital , 2004 , Boston , MA


Dr. Nigrovic graduated from Amherst College in philosophy and obtained his medical doctorate at Harvard Medical School. He trained in pediatrics and internal medicine at the Harvard Combined Med/Peds Program before completing fellowship in pediatric and adult rheumatology at Boston Children’s Hospital and the Brigham and Women’s Hospital, joining the staff of both hospitals in 2004. In 2021 he became Chief of the Division of Immunology at Boston Children’s Hospital. He also directs the Brigham’s Center for Adults with Pediatric Rheumatic Illness (CAPRI), specializing in the long-term care of individuals with childhood-onset rheumatic disease. In his academic work, he directs the Nigrovic laboratory, a basic and translational research group focused on mechanisms of inflammation in arthritis and systemic lupus erythematosus. He is Professor of Pediatrics and holds the Prince Turki Bin Abdul Aziz Al-Saud Chair in Pediatrics at Harvard Medical School, and is an elected member of the American Society for Clinical Investigation.


  • American Board of Pediatrics, Pediatric Rheumatology
  • American Board of Internal Medicine, Adult Rheumatology


Publications powered by Harvard Catalyst Profiles

  1. Th1 polarization defines the synovial fluid T cell compartment in oligoarticular juvenile idiopathic arthritis. JCI Insight. 2021 Sep 22; 6(18). View abstract
  2. IL-1ß-driven osteoclastogenic Tregs accelerate bone erosion in arthritis. J Clin Invest. 2021 Sep 15; 131(18). View abstract
  3. Serologic response to Borrelia antigens varies with clinical phenotype in children and young adults with Lyme disease. J Clin Microbiol. 2021 Aug 11; JCM0134421. View abstract
  4. Genome editing to define the function of risk loci and variants in rheumatic disease. Nat Rev Rheumatol. 2021 08; 17(8):462-474. View abstract
  5. A multidisciplinary assessment of pain in juvenile idiopathic arthritis. Semin Arthritis Rheum. 2021 Aug; 51(4):700-711. View abstract
  6. Effects of Estradiol on Immunoglobulin G Glycosylation: Mapping of the Downstream Signaling Mechanism. Front Immunol. 2021; 12:680227. View abstract
  7. Repression of CTSG, ELANE and PRTN3-mediated histone H3 proteolytic cleavage promotes monocyte-to-macrophage differentiation. Nat Immunol. 2021 06; 22(6):711-722. View abstract
  8. The neutrotime transcriptional signature defines a single continuum of neutrophils across biological compartments. Nat Commun. 2021 05 17; 12(1):2856. View abstract
  9. Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach. J Allergy Clin Immunol. 2021 May 15. View abstract
  10. Publisher Correction: Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021 May; 17(5):306. View abstract
  11. A Picture Is Worth a Thousand Words, But Only If It Is a Good Picture. Arthritis Rheumatol. 2021 06; 73(6):912-913. View abstract
  12. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021 05; 17(5):257-269. View abstract
  13. Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children. J Clin Rheumatol. 2021 Mar 16. View abstract
  14. Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. PLoS One. 2021; 16(1):e0244187. View abstract
  15. Intraperitoneal corticosteroids for recurrent ascites in patients with Fontan circulation: Initial clinical experience. J Card Surg. 2021 Feb; 36(2):735-738. View abstract
  16. COVID-19 cytokine storm: what is in a name? Ann Rheum Dis. 2021 01; 80(1):3-5. View abstract
  17. Reply. Arthritis Rheumatol. 2021 01; 73(1):176-178. View abstract
  18. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View abstract
  19. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020 11; 146(5):925-937. View abstract
  20. Effects of estradiol on biological age measured using the glycan age index. Aging (Albany NY). 2020 Oct 13; 12(19):19756-19765. View abstract
  21. The "Infodemic" of COVID-19. Arthritis Rheumatol. 2020 11; 72(11):1806-1808. View abstract
  22. NF-E2-Related Factor 2 Regulates Interferon Receptor Expression and Alters Macrophage Polarization in Lupus. Arthritis Rheumatol. 2020 10; 72(10):1707-1720. View abstract
  23. Arthritis & Rheumatology: Evolving to Meet the Challenges of Rheumatology. Arthritis Rheumatol. 2020 08; 72(8):1254-1255. View abstract
  24. The Fyn-Stat5 cascade is required for Fc? receptor-mediated mast cell function. Cell Immunol. 2020 10; 356:104134. View abstract
  25. Identification of Prevotella Oralis as a possible target antigen in children with Enthesitis related arthritis. Clin Immunol. 2020 07; 216:108463. View abstract
  26. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020 07; 72(7):1059-1063. View abstract
  27. Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart. Clin Immunol. 2020 06; 215:108411. View abstract
  28. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020 03 26; 5(6). View abstract
  29. Two- and three-color STORM analysis reveals higher-order assembly of leukotriene synthetic complexes on the nuclear envelope of murine neutrophils. J Biol Chem. 2020 04 24; 295(17):5761-5770. View abstract
  30. Analysis of peripheral blood ADA1 and ADA2 levels in children and adults. Response to: 'Total adenosine deaminase highly correlated with adenosine deaminase 2 activity in serum' by Gao et al. Ann Rheum Dis. 2020 Feb 13. View abstract
  31. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol. 2020 06; 145(6):1664-1672.e10. View abstract
  32. Differential Responsiveness of Monocyte and Macrophage Subsets to Interferon. Arthritis Rheumatol. 2020 01; 72(1):100-113. View abstract
  33. Megakaryocyte emperipolesis: a new frontier in cell-in-cell interaction. Platelets. 2020 Aug 17; 31(6):700-706. View abstract
  34. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020 02; 79(2):225-231. View abstract
  35. IgG Fc glycosylation as an axis of humoral immunity in childhood. J Allergy Clin Immunol. 2020 02; 145(2):710-713.e9. View abstract
  36. PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight. 2019 10 17; 4(20). View abstract
  37. SerpinB1 controls encephalitogenic T helper cells in neuroinflammation. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20635-20643. View abstract
  38. Storm Warning: Lung Disease in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2019 11; 71(11):1773-1775. View abstract
  39. Implications of juvenile idiopathic arthritis genetic risk variants for disease pathogenesis and classification. Curr Opin Rheumatol. 2019 09; 31(5):401-410. View abstract
  40. Early progression to active tuberculosis is a highly heritable trait driven by 3q23 in Peruvians. Nat Commun. 2019 08 21; 10(1):3765. View abstract
  41. High-dimensional analysis reveals a pathogenic role of inflammatory monocytes in experimental diffuse alveolar hemorrhage. JCI Insight. 2019 08 08; 4(15). View abstract
  42. Increased ILC3s associated with higher levels of IL-1ß aggravates inflammatory arthritis in mice lacking phagocytic NADPH oxidase. Eur J Immunol. 2019 11; 49(11):2063-2073. View abstract
  43. A role for G protein-coupled receptor 137b in bone remodeling in mouse and zebrafish. Bone. 2019 10; 127:104-113. View abstract
  44. ZFYVE21 is a complement-induced Rab5 effector that activates non-canonical NF-?B via phosphoinosotide remodeling of endosomes. Nat Commun. 2019 05 21; 10(1):2247. View abstract
  45. Megakaryocyte emperipolesis mediates membrane transfer from intracytoplasmic neutrophils to platelets. Elife. 2019 05 01; 8. View abstract
  46. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol. 2019 06; 71(6):846-863. View abstract
  47. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019 06; 71(6):717-734. View abstract
  48. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken). 2019 06; 71(6):703-716. View abstract
  49. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 2019 06; 71(6):864-877. View abstract
  50. Antibody-dependent and -independent mechanisms of inflammatory arthritis. JCI Insight. 2019 03 07; 4(5). View abstract
  51. Neutrophil Heterogeneity as Therapeutic Opportunity in Immune-Mediated Disease. Front Immunol. 2019; 10:346. View abstract
  52. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019 Feb 14; 17(1):7. View abstract
  53. Differential attenuation of ß2 integrin-dependent and -independent neutrophil migration by Ly6G ligation. Blood Adv. 2019 02 12; 3(3):256-267. View abstract
  54. The organization of leukotriene biosynthesis on the nuclear envelope revealed by single molecule localization microscopy and computational analyses. PLoS One. 2019; 14(2):e0211943. View abstract
  55. Juvenile Idiopathic Arthritis: An Idea Whose Time Has Gone? J Rheumatol. 2019 02; 46(2):124-126. View abstract
  56. Megakaryocytes as immune cells. J Leukoc Biol. 2019 06; 105(6):1111-1121. View abstract
  57. Maestro endothelium conducts the neutrophils. Blood. 2018 10 25; 132(17):1734-1735. View abstract
  58. Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes. Nat Genet. 2018 10; 50(10):1366-1374. View abstract
  59. High-throughput identification of noncoding functional SNPs via type IIS enzyme restriction. Nat Genet. 2018 08; 50(8):1180-1188. View abstract
  60. Editorial: Toward Personalized Treatment for Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2018 08; 70(8):1172-1174. View abstract
  61. Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. J Allergy Clin Immunol. 2018 10; 142(4):1363-1365.e8. View abstract
  62. Hip Synovial Fluid Cell Counts in Children From a Lyme Disease Endemic Area. Pediatrics. 2018 05; 141(5). View abstract
  63. The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans: Toward Comparative Effectiveness in the Pediatric Rheumatic Diseases. Arthritis Rheumatol. 2018 05; 70(5):669-678. View abstract
  64. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). Clin Trials. 2018 06; 15(3):268-277. View abstract
  65. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun. 2018 02 23; 9(1):789. View abstract
  66. Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Inter-Institutional Adult Rheumatology Mentoring Program. Arthritis Care Res (Hoboken). 2018 03; 70(3):445-453. View abstract
  67. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2018 03; 70(3):409-419. View abstract
  68. Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther. 2018 01 30; 20(1):14. View abstract
  69. Mycobacterial infection induces higher interleukin-1ß and dysregulated lung inflammation in mice with defective leukocyte NADPH oxidase. PLoS One. 2017; 12(12):e0189453. View abstract
  70. High-throughput characterization of the functional impact of IgG Fc glycan aberrancy in juvenile idiopathic arthritis. Glycobiology. 2017 12 01; 27(12):1099-1108. View abstract
  71. Review: Genetics and the Classification of Arthritis in Adults and Children. Arthritis Rheumatol. 2018 01; 70(1):7-17. View abstract
  72. Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci. Arthritis Rheumatol. 2017 11; 69(11):2222-2232. View abstract
  73. Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate. Rheumatology (Oxford). 2017 09 01; 56(9):1542-1551. View abstract
  74. CD177 modulates human neutrophil migration through activation-mediated integrin and chemoreceptor regulation. Blood. 2017 11 09; 130(19):2092-2100. View abstract
  75. The metabolic regulator mTORC1 controls terminal myeloid differentiation. Sci Immunol. 2017 May 26; 2(11). View abstract
  76. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatr Rheumatol Online J. 2017 Apr 11; 15(1):23. View abstract
  77. Megakaryocytes compensate for Kit insufficiency in murine arthritis. J Clin Invest. 2017 May 01; 127(5):1714-1724. View abstract
  78. Building an ARC to Grant Success: The Aims Review Committee. Arthritis Care Res (Hoboken). 2017 04; 69(4):459-461. View abstract
  79. Estrogens regulate glycosylation of IgG in women and men. JCI Insight. 2017 02 23; 2(4):e89703. View abstract
  80. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017 02 01; 542(7639):110-114. View abstract
  81. Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. Ann Rheum Dis. 2017 04; 76(4):765-772. View abstract
  82. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci Transl Med. 2016 12 14; 8(369):369ra176. View abstract
  83. Frequency and Morbidity of Temporomandibular Joint Involvement in Adult Patients With a History of Juvenile Idiopathic Arthritis. J Oral Maxillofac Surg. 2017 Jun; 75(6):1191-1200. View abstract
  84. Quantifying Temporomandibular Joint Synovitis in Children With Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2016 12; 68(12):1795-1802. View abstract
  85. Revealing the diversity of extracellular vesicles using high-dimensional flow cytometry analyses. Sci Rep. 2016 10 27; 6:35928. View abstract
  86. The Rheumatoid Arthritis Risk Variant CCR6DNP Regulates CCR6 via PARP-1. PLoS Genet. 2016 09; 12(9):e1006292. View abstract
  87. Next-Generation Sequencing Reveals Restriction and Clonotypic Expansion of Treg Cells in Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2016 07; 68(7):1758-68. View abstract
  88. Efficacy of an Interinstitutional Mentoring Program Within Pediatric Rheumatology. Arthritis Care Res (Hoboken). 2016 05; 68(5):645-51. View abstract
  89. Editorial: 21st Century Storm Chasers: Defining Macrophage Activation Syndrome. Arthritis Rheumatol. 2016 Mar; 68(3):557-60. View abstract
  90. Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis. Ann Rheum Dis. 2016 Nov; 75(11):2022-2028. View abstract
  91. Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A. 2015 Dec 29; 112(52):15785-6. View abstract
  92. Increased pretreatment serum IFN-ß/a ratio predicts non-response to tumour necrosis factor a inhibition in rheumatoid arthritis. Ann Rheum Dis. 2016 10; 75(10):1757-62. View abstract
  93. MICL controls inflammation in rheumatoid arthritis. Ann Rheum Dis. 2016 07; 75(7):1386-91. View abstract
  94. Redox Regulation of Pro-IL-1ß Processing May Contribute to the Increased Severity of Serum-Induced Arthritis in NOX2-Deficient Mice. Antioxid Redox Signal. 2015 Oct 20; 23(12):973-84. View abstract
  95. Inhibition of inflammatory arthritis using fullerene nanomaterials. PLoS One. 2015; 10(4):e0126290. View abstract
  96. Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity. Pediatr Rheumatol Online J. 2015; 13:7. View abstract
  97. Detection and quantification of microparticles from different cellular lineages using flow cytometry. Evaluation of the impact of secreted phospholipase A2 on microparticle assessment. PLoS One. 2015; 10(1):e0116812. View abstract
  98. Evaluation of synovial mast cell functions in autoimmune arthritis. Methods Mol Biol. 2015; 1220:423-42. View abstract
  99. Reply: To PMID 24623686. Arthritis Rheumatol. 2014 Sep; 66(9):2645-6. View abstract
  100. Adding canakinumab to the Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for systemic juvenile idiopathic arthritis: Comment on the article by DeWitt et al. Arthritis Care Res (Hoboken). 2014 Sep; 66(9):1430-1. View abstract
  101. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood. 2014 Oct 02; 124(14):2173-83. View abstract
  102. Highly parallel characterization of IgG Fc binding interactions. MAbs. 2014 Jul-Aug; 6(4):915-27. View abstract
  103. IL-33/ST2 axis promotes mast cell survival via BCLXL. Proc Natl Acad Sci U S A. 2014 Jul 15; 111(28):10281-6. View abstract
  104. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014 Jun; 66(6):1405-13. View abstract
  105. Choosing Wisely: the American College of Rheumatology's Top 5 for pediatric rheumatology. Arthritis Care Res (Hoboken). 2014 May; 66(5):649-57. View abstract
  106. A119: deep sequencing analysis of the T regulatory and T effector repertoire in juvenile idiopathic arthritis. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S156. View abstract
  107. A177: Program Evaluation of the ACR/CARRA Inter-Institutional Mentoring Program (AMIGO) in Pediatric Rheumatology. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S231. View abstract
  108. A161: Novel 3-Dimensional Explant Method Facilitates the Study of Lymphocyte Populations in the Synovium and Reveals a Large Population of Resident Memory T cells in Rheumatoid Arthritis. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S209. View abstract
  109. AMIGO: a novel approach to the mentorship gap in pediatric rheumatology. J Pediatr. 2014 Feb; 164(2):226-7.e1-3. View abstract
  110. Congenital disorder of fucosylation type 2c (LADII) presenting with short stature and developmental delay with minimal adhesion defect. Hum Mol Genet. 2014 Jun 01; 23(11):2880-7. View abstract
  111. Synovial fluid findings in children with knee monoarthritis in lyme disease endemic areas. Pediatr Emerg Care. 2014 Jan; 30(1):16-9. View abstract
  112. Transition and transfer of adolescents and young adults with pediatric onset chronic disease: the patient and parent perspective. J Pediatr Rehabil Med. 2014; 7(1):43-51. View abstract
  113. Dr. Henderson, et al reply. J Rheumatol. 2013 Nov; 40(11):1926. View abstract
  114. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med. 2013 Oct 30; 5(209):209ra150. View abstract
  115. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1551-63. View abstract
  116. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013 Oct; 65(10):2499-512. View abstract
  117. Sweets are good for you: fine tuning antibodies via glycosylation. Arthritis Rheum. 2013 Oct; 65(10):2541-4. View abstract
  118. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet. 2013 Jun; 45(6):664-9. View abstract
  119. Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: a cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol. 2013 Jun; 40(6):936-42. View abstract
  120. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013 May; 123(5):2183-92. View abstract
  121. Ly6 family proteins in neutrophil biology. J Leukoc Biol. 2013 Oct; 94(4):585-94. View abstract
  122. PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis. J Autoimmun. 2013 Jun; 43:1-9. View abstract
  123. Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. J Rheumatol. 2013 Mar; 40(3):273-81. View abstract
  124. Ly6G: a work in progress--author's reply to Yipp. Blood. 2013 Jan 03; 121(1):242-3. View abstract
  125. The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. EMBO Mol Med. 2013 Feb; 5(2):235-49. View abstract
  126. Characterization of fibrinogen glycosylation and its importance for serum/plasma N-glycome analysis. J Proteome Res. 2013 Jan 04; 12(1):444-54. View abstract
  127. Interleukin-33 primes mast cells for activation by IgG immune complexes. PLoS One. 2012; 7(10):e47252. View abstract
  128. Multiple juvenile idiopathic arthritis subtypes demonstrate proinflammatory IgG glycosylation. Arthritis Rheum. 2012 Sep; 64(9):3025-33. View abstract
  129. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol. 2012 Sep; 8(9):534-42. View abstract
  130. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012 Jul; 64(7):1001-10. View abstract
  131. Ly6G ligation blocks recruitment of neutrophils via a ß2-integrin-dependent mechanism. Blood. 2012 Aug 16; 120(7):1489-98. View abstract
  132. Platelets can enhance vascular permeability. Blood. 2012 Aug 09; 120(6):1334-43. View abstract
  133. Ras guanine nucleotide-releasing protein-4 (RasGRP4) involvement in experimental arthritis and colitis. J Biol Chem. 2012 Jun 08; 287(24):20047-55. View abstract
  134. Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Res Ther. 2012 Mar 05; 14(2):R43. View abstract
  135. Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011 May-Jun; 29(3):582-8. View abstract
  136. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011 Feb; 63(2):545-55. View abstract
  137. C5a receptor enables participation of mast cells in immune complex arthritis independently of Fc? receptor modulation. Arthritis Rheum. 2010 Nov; 62(11):3322-33. View abstract
  138. Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J Biol Chem. 2010 Jul 09; 285(28):21478-86. View abstract
  139. Neutrophils in a mouse model of autoantibody-mediated arthritis: critical producers of Fc receptor gamma, the receptor for C5a, and lymphocyte function-associated antigen 1. Arthritis Rheum. 2010 Mar; 62(3):753-64. View abstract
  140. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010 Jan 29; 327(5965):580-3. View abstract
  141. Juvenile psoriatic arthritis: bathwater or baby? J Rheumatol. 2009 Sep; 36(9):1861-3. View abstract
  142. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol. 2009 Jan 01; 182(1):647-56. View abstract
  143. Genetic inversion in mast cell-deficient (Wsh) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am J Pathol. 2008 Dec; 173(6):1693-701. View abstract
  144. Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis. Arthritis Rheum. 2008 May; 58(5):1354-65. View abstract
  145. Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis. Arthritis Rheum. 2008 Jan 15; 59(1):51-8. View abstract
  146. Mast cells. Rheumatoid Arthritis. Hochberg MC, Silman AJ, Smolen JS, Weisman MH, Weinblatt ME (in press). 2008. View abstract
  147. Overview of the causes of back pain in children and adolescents. 2008. View abstract
  148. Evaluation of the child with back pain. 2008. View abstract
  149. Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS). 2008. View abstract
  150. Overview of hip pain in childhood. 2008. View abstract
  151. Hemarthrosis. 2008. View abstract
  152. Mast cells contribute to autoimmune inflammatory arthritis via tryptase•heparin complexes . (submitted). 2008. View abstract
  153. Periodic fever syndromes and other autoinflammatory diseases: An overview. 2008. View abstract
  154. Laboratory and imaging studies in rheumatology. Rudolph's Pediatrics. (in press). 2008. View abstract
  155. Mast cells. Kelley's Textbook of Rheumatology. Firestein GS, Budd RC, Harris ED, McInnes IB, Ruddy S, Sergent JS (in press). 2008; in press. View abstract
  156. Synovial mast cells: role in acute and chronic arthritis. Immunol Rev. 2007 Jun; 217:19-37. View abstract
  157. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci U S A. 2007 Feb 13; 104(7):2325-30. View abstract
  158. Mast cells in acute and chronic inflammatory arthritis. Immunol Rev. 2007; 217:19-37. View abstract
  159. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006 Nov; 54(11):3564-72. View abstract
  160. Subpopulations within juvenile psoriatic arthritis: a review of the literature. Clin Dev Immunol. 2006 Jun-Dec; 13(2-4):377-80. View abstract
  161. Extreme thrombocytosis predicts Kawasaki disease in infants. Clin Pediatr (Phila). 2006 Jun; 45(5):446-52. View abstract
  162. Care of the adult with juvenile rheumatoid arthritis. Arthritis Rheum. 2006 Apr 15; 55(2):208-16. View abstract
  163. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med. 2006 Apr 17; 203(4):837-42. View abstract
  164. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol. 2006 Mar; 7(3):284-92. View abstract
  165. Innate immunity and immune complexes in rheumatoid arthritis. Rheumatoid Arthritis: New Frontiers in Pathogenesis and Treatment, G.S. Firestein, G.S. Panayi, F.A. Wollheim (eds.). 2006. View abstract
  166. Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis. Pediatrics. 2005 Jul; 116(1):e89-93. View abstract
  167. Mast cells in autoantibody responses and arthritis. Novartis Found Symp. 2005; 271:200-9; discussion 210-4. View abstract
  168. Anti-inflammatory and immunomodulatory therapy. Comprehensive Pediatrics, Osborn LM, DeWitt TG, First LR, Zenel JA (eds). 2005. View abstract
  169. Mast cells in inflammatory arthritis. Arthritis Res Ther. 2005; 7(1):1-11. View abstract
  170. Raynaud's phenomenon in children: a retrospective review of 123 patients. Pediatrics. 2003 Apr; 111(4 Pt 1):715-21. View abstract
  171. Spanish for Pediatric Medicine. 2003. View abstract
  172. Giant cell myocarditis in a 12-year-old girl with common variable immunodeficiency. Mayo Clin Proc. 2002 Jan; 77(1):92-6. View abstract
  173. Kawasaki syndrome and acquired heart disease. J Musculoskel Med. 2002; 19:65-75. View abstract
  174. Treatment of TRAPS with etanercept: use in pediatrics. Clin Exp Rheumatol. 2001 Jul-Aug; 19(4):484-5. View abstract
  175. Treatment of allergic asthma with monoclonal anti-IgE antibody. Pediatrics. 2001; 108:S566-567. View abstract
  176. Tuberculosis in Los Lomas Zaragoza, Chimaltenango. 1994. View abstract